3D organotypic cultures of human heparg cells: A tool for in vitro toxicity studies

Toxicological Sciences

Volumn 133, Issue 1, 2013, Pages 67-78

  Gunness, Patrina ^a   Mueller, Daniel ^b   Shevchenko, Valery ^c   Heinzle, Elmar ^b   Ingelman Sundberg, Magnus ^a   Noor, Fozia ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SAARLAND UNIVERSITY   (Germany)

^c Biopredic International Ltd   (France)

Author keywords

3D cultivation; HepaRG; Hepatotoxicity; Organotypic

Indexed keywords

ALBUMIN; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; GLUCOSE; LIVER ENZYME; MULTIDRUG RESISTANCE PROTEIN 2; PARACETAMOL; ROSIGLITAZONE; TROGLITAZONE;

ARTICLE; CELL CULTURE; CELL LINE; CELL STRUCTURE; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ACTIVITY; HANGING DROP METHOD; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER FUNCTION; LIVER TOXICITY; PROCEDURES; PROTEIN EXPRESSION; SPHEROID CELL; THREE DIMENSIONAL ORGANOTYPIC CULTURE;

ACETAMINOPHEN; ALBUMINS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CHROMANS; CYTOCHROME P-450 ENZYME SYSTEM; HEPATOCYTES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LIVER; P-GLYCOPROTEINS; SPHEROIDS, CELLULAR; THIAZOLIDINEDIONES; TOXICITY TESTS, ACUTE; UREA;

EID: 84876802415     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kft021     Document Type: Article

References (72)

1. Abu-Absi, S. F., Friend, J. R., Hansen, L. K., and Hu, W. S. (2002). Structural polarity and functional bile canaliculi in rat hepatocyte spheroids. Exp. Cell Res. 274, 56-67.
2. Aninat, C., Piton, A., Glaise, D., Le Charpentier, T., Langouët, S., Morel, F., Guguen-Guillouzo, C., and Guillouzo, A. (2006). Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab. Dispos. 34, 75-83.
3. Antherieu, S., Chesné, C., Li, R., Guguen-Guillouzo, C., and Guillouzo, A. (2012). Optimization of the HepaRG cell model for drug metabolism and toxicity studies. Toxicol. In Vitro 26, 1278-1285.
4. Bae, M. A., Rhee, H., and Song, B. J. (2003). Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines. Toxicol. Lett. 139, 67-75.
5. Bazou, D., Coakley, W. T., Hayes, A. J., and Jackson, S. K. (2008). Long-term viability and proliferation of alginate-encapsulated 3-D HepG2 aggregates formed in an ultrasound trap. Toxicol. In Vitro 22, 1321-1331.
6. Bedoucha, M., Atzpodien, E., and Boelsterli, U. A. (2001). Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J. Hepatol. 35, 17-23.
7. Bokhari, M., Carnachan, R. J., Cameron, N. R., and Przyborski, S. A. (2007). Culture of HepG2 liver cells on three dimensional polystyrene scaffolds enhances cell structure and function during toxicological challenge. J. Anat. 211, 567-576.
8. Cerec, V., Glaise, D., Garnier, D., Morosan, S., Turlin, B., Drenou, B., Gripon, P., Kremsdorf, D., Guguen-Guillouzo, C., and Corlu, A. (2007). Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 45, 957-967.
9. Chojkier, M. (2005). Troglitazone and liver injury: In search of answers. Hepatology 41, 237-246.
10. Clark, S., Francis, P. S., Conlan, X. A., and Barnett, N. W. (2007). Determination of urea using high-performance liquid chromatography with fluorescence detection after automated derivatisation with xanthydrol. J. Chromatogr. A 1161, 207-213.
11. Coecke, S., Ahr, H., Blaauboer, B. J., Bremer, S., Casati, S., Castell, J., Combes, R., Corvi, R., Crespi, C. L., Cunningham, M. L., et al. (2006). Metabolism: A bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54. Altern. Lab. Anim. 34, 49-84.
12. Darnell, M., Schreiter, T., Zeilinger, K., Urbaniak, T., Söderdahl, T., Rossberg, I., Dillnér, B., Berg, A. L., Gerlach, J. C., and Andersson, T. B. (2011). Cytochrome P450-dependent metabolism in HepaRG cells cultured in a dynamic three-dimensional bioreactor. Drug Metab. Dispos. 39, 1131-1138.
13. Darnell, M., Ulvestad, M., Ellis, E., Weidolf, L., and Andersson, T. B. (2012). In vitro evaluation of major in vivo drug metabolic pathways using primary human hepatocytes and HepaRG cells in suspension and a dynamic threedimensional bioreactor system. J. Pharmacol. Exp. Ther. 343, 134-144.
14. Dixit, V. A., and Bharatam, P. V. (2011). Toxic metabolite formation from Troglitazone (TGZ): New insights from a DFT study. Chem. Res. Toxicol. 24, 1113-1122.
15. Drewitz, M., Helbling, M., Fried, N., Bieri, M., Moritz, W., Lichtenberg, J., and Kelm, J. M. (2011). Towards automated production and drug sensitivity testing using scaffold-free spherical tumor microtissues. Biotechnol. J. 6, 1488-1496.
16. Edling, Y., Sivertsson, L. K., Butura, A., Ingelman-Sundberg, M., and Ek, M. (2009). Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol. In Vitro 23, 1387-1395.
17. Funk, C., Ponelle, C., Scheuermann, G., and Pantze, M. (2001). Cholestatic potential of troglitazone as a possible factor contributing to troglitazoneinduced hepatotoxicity: In vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol. Pharmacol. 59, 627-635.
18. Gibb, I. A., and Anderson, B. J. (2008). Paracetamol (acetaminophen) pharmacodynamics: Interpreting the plasma concentration. Arch. Dis. Child. 93, 241-247.
19. Godoy, P., Hengstler, J. G., Ilkavets, I., Meyer, C., Bachmann, A., Müller, A., Tuschl, G., Mueller, S. O., and Dooley, S. (2009). Extracellular matrix modulates sensitivity of hepatocytes to fibroblastoid dedifferentiation and transforming growth factor beta-induced apoptosis. Hepatology 49, 2031-2043.
20. Griffith, L. G., and Swartz, M. A. (2006). Capturing complex 3D tissue physiology in vitro. Nat. Rev. Mol. Cell Biol. 7, 211-224.
21. Gripon, P., Rumin, S., Urban, S., Le Seyec, J., Glaise, D., Cannie, I., Guyomard, C., Lucas, J., Trepo, C., and Guguen-Guillouzo, C. (2002). Infection of a human hepatoma cell line by hepatitis B virus. Proc. Natl. Acad. Sci. U.S.A. 99, 15655-15660.
22. Guillouzo, A. (1998). Liver cell models in in vitro toxicology. Environ. Health Perspect. 106(Suppl 2), 511-532.
23. Guillouzo, A., Corlu, A., Aninat, C., Glaise, D., Morel, F., and Guguen-Guillouzo, C. (2007). The human hepatoma HepaRG cells: A highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem. Biol. Interact. 168, 66-73.
24. He, K., Talaat, R. E., Pool, W. F., Reily, M. D., Reed, J. E., Bridges, A. J., and Woolf, T. F. (2004). Metabolic activation of troglitazone: Identification of a reactive metabolite and mechanisms involved. Drug Metab. Dispos. 32, 639-646.
25. Isley, W. L. (2003). Hepatotoxicity of thiazolidinediones. Expert Opin. Drug Saf. 2, 581-586.
26. Jaeschke, H. (2007). Troglitazone hepatotoxicity: Are we getting closer to understanding idiosyncratic liver injury? Toxicol. Sci. 97, 1-3.
27. Jedlitschky, G., Hoffmann, U., and Kroemer, H. K. (2006). Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opin. Drug Metab. Toxicol. 2, 351-366.
28. Jia, D. M., Tabaru, A., Akiyama, T., Abe, S., and Otsuki, M. (2000). Troglitazone prevents fatty changes of the liver in obese diabetic rats. J. Gastroenterol. Hepatol. 15, 1183-1191.
29. Jones, M. E., Berry, M. N., and Phillips, J. W. (2002). Futile cycles revisited: A markov chain model of simultaneous glycolysis and gluconeogenesis. J. Theor. Biol. 217, 509-523.
30. Josse, R., Aninat, C., Glaise, D., Dumont, J., Fessard, V., Morel, F., Poul, J. M., Guguen-Guillouzo, C., and Guillouzo, A. (2008). Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies. Drug Metab. Dispos. 36, 1111-1118.
31. Kanebratt, K. P., and Andersson, T. B. (2008). Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab. Dispos. 36, 1444-1452.
32. Kassahun, K., Pearson, P. G., Tang, W., McIntosh, I., Leung, K., Elmore, C., Dean, D., Wang, R., Doss, G., and Baillie, T. A. (2001). Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol. 14, 62-70.
33. Kelm, J. M., Ehler, E., Nielsen, L. K., Schlatter, S., Perriard, J. C., and Fussenegger, M. (2004). Design of artificial myocardial microtissues. Tissue Eng. 10, 201-214.
34. Kelm, J. M., and Fussenegger, M. (2004). Microscale tissue engineering using gravity-enforced cell assembly. Trends Biotechnol. 22, 195-202.
35. Kelm, J. M., Timmins, N. E., Brown, C. J., Fussenegger, M., and Nielsen, L. K. (2003). Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types. Biotechnol. Bioeng. 83, 173-180.
36. Kim, J. A., Han, E., Eun, C. J., Tak, Y. K., and Song, J. M. (2012). Real-time concurrent monitoring of apoptosis, cytosolic calcium, and mitochondria permeability transition for hypermulticolor high-content screening of druginduced mitochondrial dysfunction-mediated hepatotoxicity. Toxicol. Lett. 214, 175-181.
37. Knockaert, L., Descatoire, V., Vadrot, N., Fromenty, B., and Robin, M. A. (2011). Mitochondrial CYP2E1 is sufficient to mediate oxidative stress and cytotoxicity induced by ethanol and acetaminophen. Toxicol. In Vitro 25, 475-484.
38. LeCluyse, E. L. (2001). Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur. J. Pharm. Sci. 13, 343-368.
39. Leite, S. B., Wilk-Zasadna, I., Zaldivar, J. M., Airola, E., Reis-Fernandes, M. A., Mennecozzi, M., Guguen-Guillouzo, C., Chesne, C., Guillou, C., Alves, P. M., et al. (2012). Three-dimensional HepaRG model as an attractive tool for toxicity testing. Toxicol. Sci. 130, 106-116.
40. Lim, P. L., Liu, J., Go, M. L., and Boelsterli, U. A. (2008). The mitochondrial superoxide/thioredoxin-2/Ask1 signaling pathway is critically involved in troglitazone-induced cell injury to human hepatocytes. Toxicol. Sci. 101, 341-349.
41. Lin, R. Z., Chou, L. F., Chien, C. C., and Chang, H. Y. (2006). Dynamic analysis of hepatoma spheroid formation: Roles of E-cadherin and beta1-integrin. Cell Tissue Res. 324, 411-422.
42. Lin, R. Z., Lin, R. Z., and Chang, H. Y. (2008). Recent advances in three-dimensional multicellular spheroid culture for biomedical research. Biotechnol. J. 3, 1172-1184.
43. Lipscomb, J. C., Teuschler, L. K., Swartout, J., Popken, D., Cox, T., and Kedderis, G. L. (2003). The impact of cytochrome P450 2E1-dependent metabolic variance on a risk-relevant pharmacokinetic outcome in humans. Risk Anal. 23, 1221-1238.
44. Lloyd, S., Hayden, M. J., Sakai, Y., Fackett, A., Silber, P. M., Hewitt, N. J., and Li, A. P. (2002). Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors. Chem. Biol. Interact. 142, 57-71.
45. Masubuchi, Y., Kano, S., and Horie, T. (2006). Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. Toxicology 222, 233-239.
46. McGill, M. R., Yan, H. M., Ramachandran, A., Murray, G. J., Rollins, D. E., and Jaeschke, H. (2011). HepaRG cells: A human model to study mechanisms of acetaminophen hepatotoxicity. Hepatology 53, 974-982.
47. Miranda, J. P., Leite, S. B., Muller-Vieira, U., Rodrigues, A., Carrondo, M. J., and Alves, P. M. (2009). Towards an extended functional hepatocyte in vitro culture. Tissue Eng. Part C. Methods 15, 157-167.
48. Miranda, J. P., Rodrigues, A., Tostões, R. M., Leite, S., Zimmerman, H., Carrondo, M. J., and Alves, P. M. (2010). Extending hepatocyte functionality for drug-testing applications using high-viscosity alginate-encapsulated three-dimensional cultures in bioreactors. Tissue Eng. Part C. Methods 16, 1223-1232.
49. Mitchell, J. R., Jollow, D. J., Potter, W. Z., Davis, D. C., Gillette, J. R., and Brodie, B. B. (1973). Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J. Pharmacol. Exp. Ther. 187, 185-194.
50. Mueller, D., Koetemann, A., and Noor, F. (2011a). Organotypic cultures of HepG2 cells for in vitro toxicity studies. J. Bioeng. Biomed. Sci. S2, 2.
51. Mueller, D., Tascher, G., Damm, G., Nüssler, A. K., Heinzle, E., and Noor, F. (2013). Real-time in situ viability assessment in a 3D bioreactor with liver cells using resazurin assay. Cytotechnology 65, 297-305.
52. Mueller, D., Tascher, G., Müller-Vieira, U., Knobeloch, D., Nuessler, A. K., Zeilinger, K., Heinzle, E., and Noor, F. (2011b). In-depth physiological characterization of primary human hepatocytes in a 3D hollow-fiber bioreactor. J. Tissue Eng. Regen. Med. 5, e207-e218.
53. Niklas, J., Noor, F., and Heinzle, E. (2009). Effects of drugs in subtoxic concentrations on the metabolic fluxes in human hepatoma cell line Hep G2. Toxicol. Appl. Pharmacol. 240, 327-336.
54. Nozawa, T., Sugiura, S., Nakajima, M., Goto, A., Yokoi, T., Nezu, J., Tsuji, A., and Tamai, I. (2004). Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: Implications for understanding troglitazone hepatotoxicity. Drug Metab. Dispos. 32, 291-294.
55. Ogimura, E., Sekine, S., and Horie, T. (2011). Bile salt export pump inhibitors are associated with bile acid-dependent drug-induced toxicity in sandwich-cultured hepatocytes. Biochem. Biophys. Res. Commun. 416, 313-317.
56. Oshikata, A., Matsushita, T., and Ueoka, R. (2011). Enhancement of drug efflux activity via MDR1 protein by spheroid culture of human hepatic cancer cells. J. Biosci. Bioeng. 111, 590-593.
57. Perez-Ortiz, J. M., Tranque, P., Burgos, M., Vaquero, C. F., and Llopis, J. (2007). Glitazones induce astroglioma cell death by releasing reactive oxygen species from mitochondria: Modulation of cytotoxicity by nitric oxide. Mol. Pharmacol. 72, 407-417.
58. Phillips, J. W., Jones, M. E., and Berry, M. N. (2002). Implications of the simultaneous occurrence of hepatic glycolysis from glucose and gluconeogenesis from glycerol. Eur. J. Biochem. 269, 792-797.
59. Saha, S., Chan, D. S., Lee, C. Y., Wong, W., New, L. S., Chui, W. K., Yap, C. W., Chan, E. C., and Ho, H. K. (2012). Pyrrolidinediones reduce the toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer properties. Eur. J. Pharmacol. 697, 13-23.
60. Sakai, Y., Yamagami, S., and Nakazawa, K. (2010). Comparative analysis of gene expression in rat liver tissue and monolayer- and spheroid-cultured hepatocytes. Cells. Tissues. Organs (Print). 191, 281-288.
61. Shiau, C. W., Yang, C. C., Kulp, S. K., Chen, K. F., Chen, C. S., Huang, J. W., and Chen, C. S. (2005). Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Res. 65, 1561-1569.
62. Sigrist, S., Bedoucha, M., and Boelsterli, U. A. (2000). Down-regulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes. Biochem. Pharmacol. 60, 67-75.
63. Strigun, A., Wahrheit, J., Beckers, S., Heinzle, E., and Noor, F. (2011). Metabolic profiling using HPLC allows classification of drugs according to their mechanisms of action in HL-1 cardiomyocytes. Toxicol. Appl. Pharmacol. 252, 183-191.
64. Tamura, T., Koide, N., Hada, H., Shiraha, H., and Tsuji, T. (1995). Gene expression of liver-specific proteins in hepatocyte spheroids in primary culture. Acta Med. Okayama 49, 161-167.
65. Tettey, J. N., Maggs, J. L., Rapeport, W. G., Pirmohamed, M., and Park, B. K. (2001). Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chem. Res. Toxicol. 14, 965-974.
66. Tuschl, G., Lauer, B., and Mueller, S. O. (2008). Primary hepatocytes as a model to analyze species-specific toxicity and drug metabolism. Expert Opin. Drug Metab. Toxicol. 4, 855-870.
67. Van de Bovenkamp, M., Groothuis, G. M., Meijer, D. K., and Olinga, P. (2007). Liver fibrosis in vitro: Cell culture models and precision-cut liver slices. Toxicol. In Vitro 21, 545-557.
68. van Zijl, F., and Mikulits, W. (2010). Hepatospheres: Three dimensional cell cultures resemble physiological conditions of the liver. World J. Hepatol. 2, 1-7.
69. Watanabe, T., Furukawa, T., Sharyo, S., Ohashi, Y., Yasuda, M., Takaoka, M., and Manabe, S. (2000). Effect of troglitazone on the liver of a Gunn rat model of genetic enzyme polymorphism. J. Toxicol. Sci. 25, 423-431.
70. Watanabe, T., Ohashi, Y., Yasuda, M., Takaoka, M., Furukawa, T., Yamoto, T., Sanbuissho, A., and Manabe, S. (1999). Was it not possible to predict liver dysfunction caused by troglitazone during the nonclinical safety studies? Reevaluat. Safe. 30, 537-546.
71. Yamamoto, Y., Yamazaki, H., Ikeda, T., Watanabe, T., Iwabuchi, H., Nakajima, M., and Yokoi, T. (2002). Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells. Drug Metab. Dispos. 30, 155-160.
72. Zeilinger, K., Schreiter, T., Darnell, M., Söderdahl, T., Lübberstedt, M., Dillner, B., Knobeloch, D., Nüssler, A. K., Gerlach, J. C., and Andersson, T. B. (2011). Scaling down of a clinical three-dimensional perfusion multicompartment hollow fiber liver bioreactor developed for extracorporeal liver support to an analytical scale device useful for hepatic pharmacological in vitro studies. Tissue Eng. Part C. Methods 17, 549-556.